The α7 subunit of the nicotinic receptor, a ligand gated ion channel with an affinity for nicotine, has long been implicated in the pathophysiology of schizophrenia due to the extremely high rate of smoking within the patient population. However, the exact role of the receptor has never fully been determined. In the following studies, various functions the receptor may assume in disease state are evaluated. There is a strong relationship between the immune system and schizophrenia, with the α7 subunit possibly serving as the link between the two. One of the following studies looks at the possibility of the receptor functioning as antigen in an autoimmune response. Blood sera of schizophrenic patients, as well as controls, were analyzed for the presence of antibodies to the α7 subunit of the nicotinic receptor. A sensitive ligand-based assay revealed schizophrenic patients could possess a pathogenic level of antibody that may exacerbate the degenerative nature of the disease, allowing for the possibility that receptor antibodies may serve as a contributing factor in the etiology of the disorder in at least a subset of patients. In other studies, the expression of the α7 receptor was investigated. Recombinant α7 receptor production has eluded researchers in non-mammalian species and this was the focus of our initial studies. In general, the lack of sufficient molecular recombinant techniques utilizing the receptor makes characterization of the α7 receptor and it's specific protein interactions difficult to evaluate. The regulatory mechanisms of the nicotinic receptor α7 subunit production and receptor formation have yet to be completely elucidated. Results in this investigation found a relationship between a functional CRE-element in the promoter region.

Three-finger toxins (3FTX) are a group of peptides that affect multiple receptor types. One group of proteins affected by 3FTX are nicotinic acetylcholine receptors (nAChR). Structural information on how neurotoxins interact with nAChR is limited and is confined to a small group of neurotoxins. Therefore, in silico methods are valuable in understanding the interactions between 3FTX and different nAChR subtypes, but there are no established protocols to model 3FTX–nAChR interactions. We followed a homology modeling and protein docking protocol to address this issue and tested its success on three different systems. First, neurotoxin peptides co-crystallized with acetylcholine binding protein (AChBP) were re-docked to assess whether Rosetta protein–protein docking can reproduce the native poses. Second, experimental data on peptide binding to AChBP was used to test whether the docking protocol can qualitatively distinguish AChBP-binders from non-binders. Finally, we docked eight peptides with known α7 and muscle-type nAChR binding properties to test whether the protocol can explain the differential activities of the peptides at the two receptor subtypes. Overall, the docking protocol predicted the qualitative and some specific aspects of 3FTX binding to nAChR with reasonable success and shed light on unknown aspects of 3FTX binding to different receptor subtypes.

No description available.

<p>Ionizing radiation is without a doubt an invaluable tool in diagnostic imaging as well as radiation therapy. With the growing number of medical and occupational exposures, together with challenges against the LNT model, low dose exposures and non-targeted effects have been subject to intensive research. Additionally, with the advances in the field of radiation therapy and longer life expectancy after the treatment, the risks associated with second malignancies following radiation therapy for various cancers has received a tremendous amount of attention. On the other hand, nicotine, as the addictive component of tobacco has been known for its adverse health effects and its relation to various types of cancers, accounting for one in 10 adult deaths worldwide. Both nicotine and low doses of radiation are amongst the stressors that widely affect the public. Surprisingly, the interactions between low-dose effects and nicotine exposure have not received the proper scientific attention. Our group has been involved in investigation of the non-targeted effects of radiation with a variety of endpoints. Different natural compounds and signalling molecules have also been studied in our lab for their possible role or contribution to bystander signalling. This research involves the study of the impact of nicotine on radiation-induced bystander effects and also radioadaptive responses. Different concentrations of nicotine were used to study the kinetics of the drug as well as any detrimental or modifying effects when used together with radiation. It was shown that nicotine has a protective effect on survival of the cells in certain concentrations that follows a biphasic model. Similar bimodal behaviour was observed with bystander effect. No adaptation to a challenge dose of radiation occurred as a result of incubation with varying concentrations of nicotine, nor was such an effect shown with a priming dose of radiation. The results of the present study suggest that nicotine has a complicated effect on the cells which can vary significantly depending on the concentrations used and also the duration of exposure. nAChRs may have an important role in the response of the bystander cells when nicotine is involved as the results showed a shift in the response of the receptors to nicotine. This thesis is aimed to shed light on the impact of nicotine and initiate more detailed investigations on pathways through which these effects are mediated.</p> / Master of Science (MSc)

Introdução: A grande variabilidade individual em resposta a fármacos antitabagismo sugere que tratamentos específicos podem ser mais efetivos em determinados subgrupos de fumantes. No contexto de medicina personalizada, o principal objetivo do presente estudo foi avaliar se polimorfismos nos genes CHRNA4, CHRNB2, CYP2B6 e ANKK1 estão associados com a resposta às terapias de cessação tabágica em pacientes provenientes de um programa de assistência ao fumante. Métodos: Estudo de coorte com 483 pacientes fumantes que receberam tratamento farmacológico (vareniclina, vareniclina e bupropiona, bupropiona em monoterapia ou coadministrada com terapia de reposição nicotínica). O sucesso na cessação tabágica foi considerado para os pacientes que completaram 6 meses de abstinência contínua. O teste de Fagerström para a dependência à nicotina (FTND) e o escore de consumo situacional Issa foram utilizados para avaliar a dependência à nicotina. Os polimorfismos CHRNA4 (rs1044396 e rs2236196), CHRNB2 (rs2072660 e rs2072661) e ANKK1 (rs1800497) foram genotipados pela análise da curva de melting e os polimorfismos CYP2B6 *9 (rs3745274), *4 (rs2279343), *5 (rs3211371) foram genotipados por restrição enzimática. Resultados: Os pacientes com o genótipo CC para o polimorfismo CHRNA4 (rs10443196) obtiveram menor taxa de sucesso no tratamento com vareniclina (29,5%) em comparação com os portadores dos genótipos CT ou TT (50,9%) (P=0,007; n=167). Os genótipos CT ou TT foram associados com maior odds ratio para o sucesso (OR=1,67; IC 95%=1,10-2,53; P=0,02), em um modelo multivariado. Os pacientes com o genótipo AA para o polimorfismo CYP2B6 (rs2279343) obtiveram maior taxa de sucesso no tratamento com bupropiona (48,0%) em comparação com portadores dos genótipos AG ou GG (35,5%) (P=0,05; n=237). O genótipo AA foi associado com maior odds ratio para o sucesso no tratamento (OR=1,92; IC 95%=1,08-3,42; P=0,03), em um modelo multivariado. Não foram observadas diferenças significativas nos escores FTND e Issa com relação aos polimorfismos estudados. Conclusão: Os polimorfismos CHRNA4 (rs1044396) e CYP2B6 (rs2279343) estão associados com a cessação tabágica em indivíduos tratados com vareniclina e bupropiona, respectivamente. Sugere-se que estes polimorfismos influenciam a resposta farmacológica e podem ser importantes para o desenho de uma farmacoterapia individualizada / Background: The large individual variability in response to drugs for smoking cessation suggests that specific treatments can be more effective in particular subgroups of smokers. In the context of personalized medicine, the main aim of the present study was to evaluate whether the CHRNA4, CHRNB2, CYP2B6 and ANKK1 polymorphisms are associated with response to smoking cessation therapies in patients from a smoker assistance program. Methods: This cohort study enrolled 483 smoking patients patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion in monoterapy or plus nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational smoking scores were analyzed for nicotine dependence. The CHRNA4 (rs1044396 and rs2236196), CHRNB2 (rs2072660 and rs2072661) and ANKK1 rs1800497 polymorphisms were genotyped by high resolution melting analysis and the CYP2B6 *9 (rs3745274), *4 (rs2279343) and *5 (rs3211371) were genotyped by restriction fragment lenght polymorphisms. Results: Patients with CHRNA4 rs1044396 CC genotype had lower success rate in treatment with varenicline (29.5%) compared with carriers of CT or TT genotypes (50.9%) (P=0.007, n=167). The CT or TT genotypes were associated with higher odds ratio for success (OR=1.67, 95%CI=1.10-2.53, P=0.02), in a multivariate model. Patients with CYP2B6 rs2279343 AA genotype had higher success rate in treatment with bupropion (48.0%) compared with carriers of AG or GG genotypes (35.5%) (P=0.05, n=237). The AA genotype was associated with higher odds ratio for success (OR=1.92, 95%CI=1.08-3.42, P=0.03), in a multivariate model. We did not observe significant differences in the FTND and Issa scores according to the studied polymorphisms. Conclusion: The CHRNA4 rs1044396 and CYP2B6 rs2279343 are associated with smoking cessation in individuals on varenicline and bupropion terapies, respectively. We suggest that these polymorphisms influence the pharmacological response of these drugs and it might be important in the design of individualized pharmacotherapy

Introdução: A grande variabilidade individual em resposta a fármacos antitabagismo sugere que tratamentos específicos podem ser mais efetivos em determinados subgrupos de fumantes. No contexto de medicina personalizada, o principal objetivo do presente estudo foi avaliar se polimorfismos nos genes CHRNA4, CHRNB2, CYP2B6 e ANKK1 estão associados com a resposta às terapias de cessação tabágica em pacientes provenientes de um programa de assistência ao fumante. Métodos: Estudo de coorte com 483 pacientes fumantes que receberam tratamento farmacológico (vareniclina, vareniclina e bupropiona, bupropiona em monoterapia ou coadministrada com terapia de reposição nicotínica). O sucesso na cessação tabágica foi considerado para os pacientes que completaram 6 meses de abstinência contínua. O teste de Fagerström para a dependência à nicotina (FTND) e o escore de consumo situacional Issa foram utilizados para avaliar a dependência à nicotina. Os polimorfismos CHRNA4 (rs1044396 e rs2236196), CHRNB2 (rs2072660 e rs2072661) e ANKK1 (rs1800497) foram genotipados pela análise da curva de melting e os polimorfismos CYP2B6 *9 (rs3745274), *4 (rs2279343), *5 (rs3211371) foram genotipados por restrição enzimática. Resultados: Os pacientes com o genótipo CC para o polimorfismo CHRNA4 (rs10443196) obtiveram menor taxa de sucesso no tratamento com vareniclina (29,5%) em comparação com os portadores dos genótipos CT ou TT (50,9%) (P=0,007; n=167). Os genótipos CT ou TT foram associados com maior odds ratio para o sucesso (OR=1,67; IC 95%=1,10-2,53; P=0,02), em um modelo multivariado. Os pacientes com o genótipo AA para o polimorfismo CYP2B6 (rs2279343) obtiveram maior taxa de sucesso no tratamento com bupropiona (48,0%) em comparação com portadores dos genótipos AG ou GG (35,5%) (P=0,05; n=237). O genótipo AA foi associado com maior odds ratio para o sucesso no tratamento (OR=1,92; IC 95%=1,08-3,42; P=0,03), em um modelo multivariado. Não foram observadas diferenças significativas nos escores FTND e Issa com relação aos polimorfismos estudados. Conclusão: Os polimorfismos CHRNA4 (rs1044396) e CYP2B6 (rs2279343) estão associados com a cessação tabágica em indivíduos tratados com vareniclina e bupropiona, respectivamente. Sugere-se que estes polimorfismos influenciam a resposta farmacológica e podem ser importantes para o desenho de uma farmacoterapia individualizada / Background: The large individual variability in response to drugs for smoking cessation suggests that specific treatments can be more effective in particular subgroups of smokers. In the context of personalized medicine, the main aim of the present study was to evaluate whether the CHRNA4, CHRNB2, CYP2B6 and ANKK1 polymorphisms are associated with response to smoking cessation therapies in patients from a smoker assistance program. Methods: This cohort study enrolled 483 smoking patients patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion in monoterapy or plus nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational smoking scores were analyzed for nicotine dependence. The CHRNA4 (rs1044396 and rs2236196), CHRNB2 (rs2072660 and rs2072661) and ANKK1 rs1800497 polymorphisms were genotyped by high resolution melting analysis and the CYP2B6 *9 (rs3745274), *4 (rs2279343) and *5 (rs3211371) were genotyped by restriction fragment lenght polymorphisms. Results: Patients with CHRNA4 rs1044396 CC genotype had lower success rate in treatment with varenicline (29.5%) compared with carriers of CT or TT genotypes (50.9%) (P=0.007, n=167). The CT or TT genotypes were associated with higher odds ratio for success (OR=1.67, 95%CI=1.10-2.53, P=0.02), in a multivariate model. Patients with CYP2B6 rs2279343 AA genotype had higher success rate in treatment with bupropion (48.0%) compared with carriers of AG or GG genotypes (35.5%) (P=0.05, n=237). The AA genotype was associated with higher odds ratio for success (OR=1.92, 95%CI=1.08-3.42, P=0.03), in a multivariate model. We did not observe significant differences in the FTND and Issa scores according to the studied polymorphisms. Conclusion: The CHRNA4 rs1044396 and CYP2B6 rs2279343 are associated with smoking cessation in individuals on varenicline and bupropion terapies, respectively. We suggest that these polymorphisms influence the pharmacological response of these drugs and it might be important in the design of individualized pharmacotherapy

Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca²⁺ mobilising messenger in mammalian and non-mammalian cells. Studies on a variety of cell types suggest that NAADP evokes Ca²⁺ release from a lysosome-related store and via activation of a receptor distinct from either ryanodine receptors (RyR) or inositol 1,4,5-trisphosphate (IP₃) receptors (IP₃R). However, the identity of the NAADP receptor has, until now, remained elusive. In this thesis I have shown that NAADP-evoked Ca²⁺ release from lysosomes is underpinned by two-pore channels (TPCs), of which there are 3 subtypes, TPC1, TPC2 and TPC3. When stably over-expressed in HEK293 cells, TPC2 was found to be specifically targeted to lysosomes, while TPC1 and TPC3 were targeted to endosomes. Initial Ca²⁺ signals via TPC2, but not those via TPC1, were amplified into global Ca²⁺ waves by Ca²⁺-induced Ca²⁺ release (CICR) from the endoplasmic reticulum (ER) via IP₃Rs. I have shown that, consistent with a role for TPCs in NAADP-mediated Ca²⁺ release, TPC2 is expressed in pulmonary arterial smooth muscle cells (PASMCs), is likely targeted to lysosomal membranes, and that TPCs also underpin NAADP-evoked Ca²⁺ signalling in this cell type. However, and in contrast to HEK293 cells, in PASMCs NAADP evokes spatially restricted Ca²⁺ bursts that are amplified into global Ca²⁺ waves by CICR from the sarcoplasmic reticulum (SR) via a subpopulation of RyRs, but not via IP₃Rs. I have demonstrated that lysosomes preferentially co-localise with RyR subtype 3 (RyR3) in the perinuclear region of PASMCs to comprise a “trigger zone” for Ca²⁺ signalling by NAADP, away from which a propagating Ca²⁺ wave may be carried by subsequent recruitment of RyR2. The identification of TPCs as a family of NAADP receptors may further our understanding of the mechanisms that confer the versatility of Ca²⁺ signalling which is required to regulate such diverse cellular functions as gene expression, fertilization, cell growth, and ultimately cell death.

Les cortices sensoriels sont des régions cérébrales essentielles pour la perception. En particulier, le cortex visuel traite l’information visuelle en provenance de la rétine qui transite par le thalamus. Les neurones sont les unités fonctionnelles qui transforment l'information sensorielle en signaux électriques, la transfèrent vers le cortex et l'intègrent. Les neurones du cortex visuel sont spécialisés et analysent différents aspects des stimuli visuels. La force des connections entre les neurones peut être modulée par la persistance de l'activité pré-synaptique et induit une augmentation ou une diminution du signal post-synaptique à long terme. Ces modifications de la connectivité synaptique peuvent induire la réorganisation de la carte corticale, c’est à dire la représentation de ce stimulus et la puissance de son traitement cortical. Cette réorganisation est connue sous le nom de plasticité corticale. Elle est particulièrement active durant la période de développement, mais elle s’observe aussi chez l’adulte, par exemple durant l’apprentissage. Le neurotransmetteur acétylcholine (ACh) est impliqué dans de nombreuses fonctions cognitives telles que l’apprentissage ou l’attention et il est important pour la plasticité corticale. En particulier, les récepteurs nicotiniques et muscariniques du sous-type M1 et M2 sont les récepteurs cholinergiques impliqués dans l’induction de la plasticité corticale. L’objectif principal de la présente thèse est de déterminer les mécanismes de plasticité corticale induits par la stimulation du système cholinergique au niveau du télencéphale basal et de définir les effets sur l’amélioration de la perception sensorielle. Afin d’induire la plasticité corticale, j’ai jumelé des stimulations visuelles à des injections intracorticales d’agoniste cholinergique (carbachol) ou à une stimulation du télencéphale basal (neurones cholinergiques qui innervent le cortex visuel primaire). J'ai analysé les potentiels évoqués visuels (PEVs) dans le cortex visuel primaire des rats pendant 4 à 8 heures après le couplage. Afin de préciser l’action de l’ACh sur l’activité des PEVs dans V1, j’ai injecté individuellement l’antagoniste des récepteurs muscariniques, nicotiniques, α7 ou NMDA avant l’infusion de carbachol. La stimulation du système cholinergique jumelée avec une stimulation visuelle augmente l’amplitude des PEVs durant plus de 8h. Le blocage des récepteurs muscarinique, nicotinique et NMDA abolit complètement cette amélioration, tandis que l’inhibition des récepteurs α7 a induit une augmentation instantanée des PEVs. Ces résultats suggèrent que l'ACh facilite à long terme la réponse aux stimuli visuels et que cette facilitation implique les récepteurs nicotiniques, muscariniques et une interaction avec les récepteur NMDA dans le cortex visuel. Ces mécanismes sont semblables à la potentiation à long-terme, évènement physiologique lié à l’apprentissage. L’étape suivante était d’évaluer si l’effet de l’amplification cholinergique de l’entrée de l’information visuelle résultait non seulement en une modification de l’activité corticale mais aussi de la perception visuelle. J’ai donc mesuré l’amélioration de l’acuité visuelle de rats adultes éveillés exposés durant 10 minutes par jour pendant deux semaines à un stimulus visuel de type «réseau sinusoïdal» couplé à une stimulation électrique du télencéphale basal. L’acuité visuelle a été mesurée avant et après le couplage des stimulations visuelle et cholinergique à l’aide d’une tâche de discrimination visuelle. L’acuité visuelle du rat pour le stimulus d’entrainement a été augmentée après la période d’entrainement. L’augmentation de l’acuité visuelle n’a pas été observée lorsque la stimulation visuelle seule ou celle du télencéphale basal seul, ni lorsque les fibres cholinergiques ont été lésées avant la stimulation visuelle. Une augmentation à long terme de la réactivité corticale du cortex visuel primaire des neurones pyramidaux et des interneurones GABAergiques a été montrée par l’immunoréactivité au c-Fos. Ainsi, lorsque couplé à un entrainement visuel, le système cholinergique améliore les performances visuelles pour l’orientation et ce probablement par l’optimisation du processus d’attention et de plasticité corticale dans l’aire V1. Afin d’étudier les mécanismes pharmacologiques impliqués dans l’amélioration de la perception visuelle, j’ai comparé les PEVs avant et après le couplage de la stimulation visuelle/cholinergique en présence d’agonistes/antagonistes sélectifs. Les injections intracorticales des différents agents pharmacologiques pendant le couplage ont montré que les récepteurs nicotiniques et M1 muscariniques amplifient la réponse corticale tandis que les récepteurs M2 muscariniques inhibent les neurones GABAergiques induisant un effet excitateur. L’infusion d’antagoniste du GABA corrobore l’hypothèse que le système inhibiteur est essentiel pour induire la plasticité corticale. Ces résultats démontrent que l’entrainement visuel jumelé avec la stimulation cholinergique améliore la plasticité corticale et qu’elle est contrôlée par les récepteurs nicotinique et muscariniques M1 et M2. Mes résultats suggèrent que le système cholinergique est un système neuromodulateur qui peut améliorer la perception sensorielle lors d’un apprentissage perceptuel. Les mécanismes d’amélioration perceptuelle induits par l’acétylcholine sont liés aux processus d’attention, de potentialisation à long-terme et de modulation de la balance d’influx excitateur/inhibiteur. En particulier, le couplage de l’activité cholinergique avec une stimulation visuelle augmente le ratio de signal / bruit et ainsi la détection de cibles. L’augmentation de la concentration cholinergique corticale potentialise l’afférence thalamocorticale, ce qui facilite le traitement d’un nouveau stimulus et diminue la signalisation cortico-corticale minimisant ainsi la modulation latérale. Ceci est contrôlé par différents sous-types de récepteurs cholinergiques situés sur les neurones GABAergiques ou glutamatergiques des différentes couches corticales. La présente thèse montre qu’une stimulation électrique dans le télencéphale basal a un effet similaire à l’infusion d’agoniste cholinergique et qu’un couplage de stimulations visuelle et cholinergique induit la plasticité corticale. Ce jumelage répété de stimulations visuelle/cholinergique augmente la capacité de discrimination visuelle et améliore la perception. Cette amélioration est corrélée à une amplification de l’activité neuronale démontrée par immunocytochimie du c-Fos. L’immunocytochimie montre aussi une différence entre l’activité des neurones glutamatergiques et GABAergiques dans les différentes couches corticales. L’injection pharmacologique pendant la stimulation visuelle/cholinergique suggère que les récepteurs nicotiniques, muscariniques M1 peuvent amplifier la réponse excitatrice tandis que les récepteurs M2 contrôlent l’activation GABAergique. Ainsi, le système cholinergique activé au cours du processus visuel induit des mécanismes de plasticité corticale et peut ainsi améliorer la capacité perceptive. De meilleures connaissances sur ces actions ouvrent la possibilité d’accélérer la restauration des fonctions visuelles lors d’un déficit ou d’amplifier la fonction cognitive. / Sensory cortex is an essential area where sensory perception occurs. Especially visual cortex processes visual information transmitted from the retina through the thalamus. By different neuronal activation the information is segregated and sent to diverse visual area for interpretation. Neurons are the basic unit that transform sensory information into electrophysiological signal, transfer to the cortex and integrate it. Connection between neurons can be modulated depending on the persistent presynaptic activity inducing either a long-term increase or decrease of the post-synaptic activity. Modification in synaptic strength can affect large area and induce reorganization of cortical map (i.e. cortical plasticity) which changes the representation of the visual stimulus and its weight in visual processing. Cortical plasticity can occur during juvenile while forming developmental connection or in adult while acquiring novel information (i.e. learning). The neurotransmitter ACh is involved in many cognitive functions, such as learning or attention and it was demonstrated that lesioning or blocking cholinergic system diminishes cortical plasticity. It was shown that nicotinic, M1 subtype and M2 subtype muscarinic receptors are the major cholinergic receptors abundant in the cortex and implicated during cortical plasticity induction. In a first part, I analyzed visual evoked potentials (VEPs) in V1 of rats during a 4-8h period after coupling visual stimulation to an intracortical injection of ACh agonist carbachol or stimulation of basal forebrain. To clarify the action of ACh on VEP activity in V1, we individually injected muscarinic, nicotinic, α7, and NMDA receptor antagonists just before carbachol infusion. Stimulation of the cholinergic system paired with visual stimulation significantly increased VEP amplitude for long-term. Pre-inhibition of muscarinic, nicotinic and NMDA receptor completely abolished this long-term enhancement, while α7 inhibition induced an instant increase of VEP amplitude. This suggests a role of ACh in facilitating visual stimuli responsiveness which involves nicotinic and muscarinic receptors with an interaction of NMDA transmission in the visual cortex. These mechanisms were similar to long-term potentiation, a neurobiological mechanism of learning. In a second step, I evaluate whether cholinergic modulation of visual neurons results in cortical activity and visual perception changes. Awake adult rats were exposed repetitively for two weeks to an orientation-specific grating with coupling visual stimulation to an electrical stimulation of the basal forebrain. The visual acuity, as measured using a visual water maze before and after coupling visual/cholinergic stimulation was increased. The increase in visual acuity was not observed when visual or basal forebrain stimulation was performed separately nor when cholinergic fibers were selectively lesioned prior to the visual stimulation. There was a long-lasting increase in cortical reactivity of the primary visual cortex shown by c-Fos immunoreactivity of both pyramidal and GABAergic interneuron. These findings demonstrate that when coupled with visual training, the cholinergic system improves visual performance for the trained orientation probably through enhancement of attentional processes and cortical plasticity in V1 related to the ratio of excitatory/inhibitory inputs. Finally, I also investigated the different pharmacological mechanisms involved in the visual enhancement. Pre- and post-pairing visual/cholinergic stimulation VEP were compared with selective administered agonist/antagonist during the pairing. Awaken adult rats were exposed during 10 minutes per day for 1 week to an orientation specific grating with an electrical stimulation of the basal forebrain. Intracortical injection of different pharmacological agents during pairing demonstrated that nicotinic and M1 muscarinic receptors are used to amplify cortical response while M2 muscarinic receptor suppresses GABAergic neurons to disinhibit excitatory neurons. Infusion of GABAergic antagonist supported that inhibitory system is crucial to induce cortical plasticity. These findings demonstrate that visual training coupled with the cholinergic stimulation enhances the cortical plasticity mediated by nicotinic, M1 and M2 muscarinic receptors, which the latter induces a disinhibition by suppressing GABAergic neuron. The cholinergic system is a potent neuromodulatory system. Boosting this system during perceptual learning robustly enhances the sensory perception. Especially, pairing a cholinergic activation with a visual stimulation increases the signal-to-noise ratio, cue detection ability in the primary visual cortex. This cholinergic enhancement increases the strength of thalamocortical afferent to facilitate the treatment of a novel stimulus while decreasing the cortico-cortical signaling to minimize recurrent or top-down modulation. This is mediated by different cholinergic receptor subtypes located in both glutamatergic and GABAergic neurons of the different cortical layers. The mechanisms of cholinergic enhancement are closely linked to attentional processes, long-term potentiation and modulation of the excitatory/inhibitory balance. The present thesis shows that electrical stimulation of the basal forebrain has similar effect with cholinergic agonist release and pairing visual/cholinergic stimulation induces cortical plasticity. Repetitive pairing of visual/cholinergic increases visual discrimination capacity and enhances perceptual ability. This enhancement is followed by an augmentation of neuronal activity demonstrated by c-Fos immunohistochemistry. Immunoreactivity also shows difference in glutamatergic and GABAergic neurons activities between layers. Pharmacological injection during visual/cholinergic pairing suggests that nicotinic and M1 muscarinic receptor can amplify excitatory response while M2 receptor controls GABAergic activation. Altogether cholinergic system activated during visual process induces cortical plasticity and can enhance perceptual ability. Further understanding of this training has the potential to accelerate visual recovery or boost cognitive function.

Au cours de ce travail, nous avons développé des voies de synthèses convergentes et énantiosélectives en vue de préparer des analogues pyrrolidiniques des alcaloïdes de Lobelia comme nouveaux ligands des récepteurs nicotiniques à l’acétylcholine. Deux familles de ligands ont été réalisées par des méthodes d’élongation mono- ou bi-directionnelle basées respectivement sur des stratégies de désymétrisation précoce ou tardive au départ du succinaldéhyde.La première partie de ce manuscrit aborde la conception d’hybrides de lobéline, nicotine et d’agonistes naturels. Ces structures originales ont été obtenues diastéréosélectivement grâce à un intermédiaire commun issu d’une élongation monodirectionnelle du succinaldéhyde. Cette voie exploitera la chimie des iminiums masqués. La mise au point de cette synthèse s’est enrichie par la découverte et la valorisation d’une nouvelle famille de ligands chimériques.La seconde partie étudie la voie d’élongation bidirectionnelle basée sur des réactions de double aza-Michael suivies de la réduction désymétrisante tardive de pyrrolidines 2,5-phénacyl méso et pseudo-méso. Cette stratégie asymétrique s’inscrit dans une démarche d’économie d’atomes et d’étapes. La perspective majeure de ce travail est l’évaluation par électrophysiologie sur différents sous-types de récepteurs à l’acétylcholine d’une sélection de ligands hybrides.Les études de RSA menées sur ces familles de composés de haute homologie structurale permettront in fine d’améliorer les modèles prédictifs décrivant les transitions allostériques des récepteurs nicotiniques à l’acétylcholine / During this PhD work, convergent and diastereoselective routes for the preparation of pyrrolidine Lobelia alkaloid analogues have been developed as novel neuronal nicotinic receptor ligands. Two families of ligands have been synthesized by a strategy of mono- or bi-directional elongation of the succinaldehyde including early or late desymmetrization process respectively.The first part of this manuscript is dedicated to the preparation of hybrids of lobeline, nicotine and other natural agonists. These original structures have been diastereoselectively obtained thanks to a common intermediate resulting of the mono-elongation of succinaldehyde. This synthetic pathway uses the chemistry of masked iminium. The development of this strategy has been enriched by the discovery and the valorisation of a new chimeric ligand family.The second part studies the “bidirectional” elongation route, based on a ring-closing double aza-Michael reaction followed by the desymmetrizing reduction of meso and pseudo-meso 2,5-diphenacyl pyrrolidines. This asymmetric strategy constitutes a step- and atom-economical approach. The major perspective of this work is the biological evaluation of selected ligands by electrophysiology made on different nAChR subtypes.The SAR studies realized on these structurally homologue ligand families could allow the improvement of the predictive molecular models describing the allosteric conformations of the nAChRs.

Neste trabalho foi preparada uma série de onze brometo de 2-[(4-X-benzamido) etil]benzildimetilamônio, compostos I.1-I.11, série I, estruturalmente análogos à procainamida, não descritos na literatura. Os valores do coeficiente de partição, log Papp7.40, destes compostos foram determinados pelo método shake-flask e foram utilizados como parâmetro lipofílico experimental. Os valores de deslocamento químico do grupamento carbonila, &#948; 13 C=O, foram determinados e foram determinados cm um espectrómetro de ressonância magnética nuclear a 75 MHz. Adicionalmente, outros parâmetros físico-químicos foram retirados da literatura: &#960;, &#963;p, &#932;, R e MR4 ou obtidos por cálculo: log Pcalc e &#960;exp. Os valores da concentração inibitória média (IC50) capaz de reduzir a contração máxima a 50% no período de 15 minutos, foram determinados em preparações nervo frênico-músculo diafragma de camundongos. Para verificar a natureza e a contribuição relativa dos parâmetros físico-químicos frente ao bloqueio da transmissão neuromuscular foi feito uma análise de QSAR, obtendo-se equações, usando análise de regressão linear. As análises de QSAR sugerem uma dependência positiva da lipofilicidade para o bloqueio da transmissão neuromuscular expresso por pIC50, segundo o modelo proposto expresso pela equação: (Ver arquivo PDF). / In this work, a set of eleven 2-[(4-X-benzamido)ethyl]benzyl dimethylammonium bromide structurally related to procainamide was synthesized. The apparent partition coefficient values were determined by means of \"shake-flask method and were taken as lipophilic parameters. The carbonyl chemical shifts values were determined in methanol-d4 and taken as electronic parameters. Additionally, physicochemical parameters were either taken from literature: &#960;, &#963;p, &#932;, R e MR4 or calculated: log Pcalc and &#960;exp. The median inhibitory concentration values (IC50) able to reduce maximal contraction to 50% at 15 minutes was determined in phrenic nerve-diafragm muscle preparation of mices. In order to verify the nature and relative contribution of the physicochemical parameters to neuromuscular blockage, QSAR equations were derived using regression analysis. The obtained QSAR model, expressed by the equation below, suggest that lipophilicity term plays an important role to neuromuscular blockage. (See files PDF).